Shanghai Kaibao Pharmaceutical CO.,LTD.  

(Public, SHE:300039)   Watch this stock  
+0.06 (0.58%)
Feb 28 - Close
SHE real-time data - Disclaimer
Currency in CNY
Range 10.41 - 10.51
52 week 8.90 - 11.97
Open 10.44
Vol. 6.14M
Mkt cap 8.68B
P/E 30.12
EPS 0.35
Shares 829.43M

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 22.18% 20.18%
Operating margin 26.36% 23.49%
EBITD margin - 25.02%
Return on average assets 10.81% 11.91%
Return on average equity 12.79% 14.47%
Employees 1,579 -
CDP Score - -


No. 88 Chengpu Road Industrial Comprehensive Development Zne
+86-21-37572069 (Phone)
+86-21-37572069 (Fax)

Website links


Shanghai Kaibao Pharmaceutical CO., LTD. is a China-based company principally engaged in research, development, manufacture and distribution of Chinese medicines. The Company's main products are clear away heat and toxic material injections, which are applied in treatment of upper respiratory tract infections, such as cold and pneumonia; pioglitazone hydrochloride tablets, which are applied in treatment of diabetes; captopril sustained-release tablets, which are adopted in treatment of hypertension, as well as doxofylline capsules, which are applied in treatment of asthma and other diseases. The Company's products mainly include small volume injections, tablets, hard capsules, granules, mixtures, syrup and oral liquids, among others. The Company distributes its products in domestic markets. It also involves in the purchase of agricultural products.

Officers and directors

Yishan Liu Chairman of the Board
Age: 57
Liwang Ren Chief Financial Officer
Age: 43
Guoming Wang General Manager, Director
Age: 50
Jingwei Mu Secretary of the Board, Deputy General Manager
Age: 35
Shaoyong Liu Deputy General Manager, Director
Age: 49
Dongsheng Xue Deputy General Manager, Director
Age: 44
Chongbang Wang Deputy General Manager
Age: 50
Yingjun Zhu Deputy General Manager
Age: 43
Mingwei Feng Director
Age: 43
Laian Mu Director
Age: 59